GSE139031 ( miRNA )

Glioma ( glioma )

Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients with Diffuse Glioma

Cancer : 423 / Control : 157

The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.

A serum miRNA combination could be a powerful classifier for the detection of patients with brain tumors.

Serum microRNA profiles of diffuse gliomas, other primary brain tumors, primary central nervous system lymphomas (PCNSL), metastatic brain tumors (Meta), benign brain tumors, spinal schwannomas, trauma, infarction, benign disease controls, and prospectively collected non-cancer controls in a clinic.

Ohno M, Matsuzaki J, Kawauchi J, Aoki Y et al. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma. JAMA Netw Open 2019 Dec 2;2(12):e1916953. PMID: 31808923

Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).

total RNA

Cy5

miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.

Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.

3D-Gene Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).